About this trial
The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular parameters into established non-invasive risk assessment models results in risk reclassification and improves identification of patients at risk for short-term clinical worsening.
Adult patients with established Group 1 PAH undergoing routine follow-up and with available right heart catheterization (RHC) and CMR data will be consecutively enrolled. Clinical, laboratory, echocardiographic, and follow-up data will be prospectively collected over a 6-month period. Associations between multimodality imaging findings, invasive hemodynamic measurements, risk classification, and short-term clinical outcomes will be evaluated.
Eligibility criteria
Qualifiers
Adults aged 18 years or older
Diagnosis of Group 1 pulmonary arterial hypertension (PAH) according to ESC/ERS guidelines
Followed at the study center with a diagnosis of PAH
Availability of right heart catheterization (RHC) and cardiac magnetic resonance (CMR) imaging data obtained within a clinically relevant time interval
Disqualifiers
Age younger than 18 years
Pulmonary hypertension groups other than Group 1 PAH (Groups 2-5 PH)
Absence of either right heart catheterization or cardiac magnetic resonance imaging data within a clinically relevant time interval
Incomplete clinical or imaging data preventing analysis
Trial design
Treatments tested in this trial
- Not listed